<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760925</url>
  </required_header>
  <id_info>
    <org_study_id>CD0231</org_study_id>
    <nct_id>NCT04760925</nct_id>
  </id_info>
  <brief_title>Cascade Clinical Data Collection Protocol</brief_title>
  <official_title>Single Arm, Open Label, Retrospective and Prospective Clinical Data Collection to Assess CascadeTM, Non-Occlusive Remodeling Net, in Providing Temporary Assistance for Coil Embolization of Intracranial Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perflow Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perflow Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, single arm, open label, retrospective and prospective clinical&#xD;
      data collection of CascadeTM, Non-Occlusive Remodeling Net, in adults with intracranial&#xD;
      aneurysms, demonstrating the effectiveness and safety of the CascadeTM in providing temporary&#xD;
      assistance for coil embolization of intracranial aneurysms.&#xD;
&#xD;
      All consecutive eligible patients from all participating sites will be included in this&#xD;
      clinical data collection. The relevant data of the coil embolization procedure will be&#xD;
      collected via an eCRF system.&#xD;
&#xD;
      Peri procedural data on the coil embolization procedure as well as discharge, 30 days and at&#xD;
      3-6 months status will be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint - Successful coil embolization of the target intracranial aneurysm assisted by Cascade device</measure>
    <time_frame>During procedure</time_frame>
    <description>Successful coil embolization of the target intracranial aneurysm assisted by Cascade device, without coil entanglement, protrusion or prolapse into the parent vessel at the end of the procedure, as evaluated angiographically by a central core-lab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Main Safety Endpoint - Incidence of Serious Adverse Device Effects (SADE)</measure>
    <time_frame>within 30 days post procedure</time_frame>
    <description>Serious adverse device effects (SADE) occurring within 30 days post procedure, including the following safety events:&#xD;
Vessel damage related to the use of the study device that leads to dissection, perforation, hemorrhage or vasospasm.&#xD;
Thromboembolic event related to the use of the study device.&#xD;
Coil entanglement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint - Maintenance or improvement of aneurysm occlusion</measure>
    <time_frame>3-6 months post procedure</time_frame>
    <description>Maintenance or improvement of aneurysm occlusion (evaluated angiographically by a central core-lab) using modified Raymond-Roy Classification (MRRC) at 3-6 months compared to the end of the procedure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other Safety Endpoint - Incidence of all Adverse Events</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>All adverse events experienced by enrolled patients within 30 days post coil embolization procedure, regardless of relatedness to the Cascade device or the coil embolization procedure</description>
  </other_outcome>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CascadeTM, Non-Occlusive Remodeling Net</intervention_name>
    <description>Temporary assistance device for coil embolization of intracranial aneurysms</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were planned to undergo, or underwent coil embolization procedure of&#xD;
        intracranial aneurysms assisted by the Cascade device&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients must fulfill the following eligibility criteria to be included in the study:&#xD;
&#xD;
          1. Patient has been treated or planned to be treated with Cascade (Cascade device was&#xD;
             opened).&#xD;
&#xD;
          2. Patient or patient's legally authorized representative or patient's family member (if&#xD;
             approved by IEC) has signed and dated an Informed Consent Form (ICF), unless ICF is&#xD;
             waived by local IEC.&#xD;
&#xD;
          3. Coil embolization procedure of intracranial aneurysm using temporary assisting device&#xD;
             is initiated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Galit Itzhaki, B.Pharm</last_name>
    <phone>+972-3-6544011</phone>
    <phone_ext>201</phone_ext>
    <email>galiti@perflow.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guy Neuberger, B.Sc.</last_name>
    <phone>+972-3-6544011</phone>
    <phone_ext>209</phone_ext>
    <email>guyn@perflow.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UH St. Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Faculty of the Otto von Guericke University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie BÃ¶ttcher</last_name>
      <phone>+49-391-67-13192</phone>
      <email>sophie2.boettcher@med.ovgu.de</email>
    </contact>
    <investigator>
      <last_name>Anastasios Mpotsaris, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Behme, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>radprax MVZ GmbH</name>
      <address>
        <city>Solingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Wolf, R.N.</last_name>
      <phone>+49 212 2489 2217</phone>
      <email>cwolf@radprax.de</email>
    </contact>
    <investigator>
      <last_name>Hannes Nordmeyer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timo H. Phung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel HaShomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noit Brown, B.Sc</last_name>
      <phone>+972-3-5304423</phone>
      <email>noit.brown@sheba.gov.il</email>
    </contact>
    <investigator>
      <last_name>David Orion, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gal Yaniv, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the MSWiA</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nowak Blazej, M.D.</last_name>
      <phone>+48 668320448</phone>
      <email>blazejnowak90@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michal Zawadzki, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari De Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Barranco, M.D.</last_name>
      <phone>+34 689 575531</phone>
      <email>rogerbarrancopons@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roger Barranco, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Aixut, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eila B. Rivera, R.N.</last_name>
      <phone>+34 634829327</phone>
      <email>eriverboix@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alejandro W. Tomasello, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David M. Hernandez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos P. Pinana, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

